News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Highly effective preservation solutions ensuring the safety and protection of personal care products
Subscribe To Our Newsletter & Stay Updated
